Arrowstreet Capital Limited Partnership lessened its holdings in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 63.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 4,976 shares of the health services provider's stock after selling 8,594 shares during the period. Arrowstreet Capital Limited Partnership's holdings in Amedisys were worth $452,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Blue Trust Inc. raised its holdings in Amedisys by 55.1% in the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock worth $34,000 after purchasing an additional 124 shares during the period. Xponance Inc. lifted its stake in shares of Amedisys by 3.5% during the 4th quarter. Xponance Inc. now owns 4,349 shares of the health services provider's stock worth $395,000 after buying an additional 148 shares during the last quarter. Inspire Investing LLC increased its position in Amedisys by 3.6% during the 4th quarter. Inspire Investing LLC now owns 4,405 shares of the health services provider's stock worth $400,000 after buying an additional 155 shares during the period. Nisa Investment Advisors LLC grew its position in shares of Amedisys by 1.2% during the 4th quarter. Nisa Investment Advisors LLC now owns 15,150 shares of the health services provider's stock worth $1,375,000 after purchasing an additional 180 shares in the last quarter. Finally, Retirement Systems of Alabama raised its holdings in Amedisys by 0.5% in the 4th quarter. Retirement Systems of Alabama now owns 39,822 shares of the health services provider's stock valued at $3,615,000 after acquiring an additional 181 shares in the last quarter. Institutional investors and hedge funds own 94.36% of the company's stock.
Amedisys Stock Performance
Shares of Amedisys stock traded up $0.14 during trading hours on Tuesday, hitting $91.58. 111,386 shares of the company's stock traded hands, compared to its average volume of 401,020. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The stock has a market capitalization of $3.00 billion, a price-to-earnings ratio of 36.34, a PEG ratio of 1.78 and a beta of 0.89. Amedisys, Inc. has a 12-month low of $82.15 and a 12-month high of $98.95. The company has a fifty day simple moving average of $92.17 and a 200-day simple moving average of $91.98.
Amedisys (NASDAQ:AMED - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.05 by ($0.09). The business had revenue of $598.05 million during the quarter, compared to analysts' expectations of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. Equities research analysts anticipate that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Separately, Stephens reissued an "equal weight" rating and issued a $101.00 price objective on shares of Amedisys in a research note on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $101.00.
View Our Latest Analysis on AMED
About Amedisys
(
Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Read More
Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
